Bristol Myers Squibb Presents 56-Week Results From Phase 3 SCOUT-HCM Clinical Trial In Late-Breaker Presentation At HCMS Scientific Sessions

With a consistent efficacy and safety profile through 56-weeks of follow-up, the Phase 3 SCOUT-HCM clinical trial further reinforces Camzyos as the first approved treatment for pediatric patients ≥30 kg with symptomatic oHCM

No patient treated with Camzyos experienced left ventricular ejection fraction (LVEF) <50% over the 56-week evaluation period, and no new safety signals were reported

Additional presentations will be shared at the American Heart Association’s Scientific Sessions 2026 that expand on the breadth of evidence supporting Camzyos across clinical and real-world settings in diverse patient populations

Bristol Myers Squibb (NYSE:BMY) today presented 56-week results from the Phase 3 SCOUT-HCM clinical trial in a late-breaker presentation at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions, taking place November 6, 2026, in Chicago, Illinois. The SCOUT-HCM clinical trial evaluated the efficacy and safety of Camzyos (mavacamten) in pediatric patients aged 12 to <18 years with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). These additional data build upon confidence in Camzyos, whichhas the broadest indication of any cardiac myosin inhibitor (CMI) and is the first CMI approved for pediatric patients with symptomatic oHCM. Results from the 56-week data are consistent with previously reported 28-week results from the trial. Bristol Myers Squibb will be sharing additional presentations that add to the breadth of clinical and real-world data supporting the use of Camzyos across patient populations, reinforcing the consistent efficacy and safety profile of Camzyos as a treatment for symptomatic oHCM, at the American Heart Association’s Scientific Sessions 2026 taking place November 6 – 9, 2026, in Chicago, Illinois.